Stock 1652 FUSEN PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Fusen Pharmaceutical Company Limited Stock

Equities

1652

KYG370981030

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 21:56:39 2024-05-02 EDT 		5-day change 1st Jan Change
0.88 HKD -1.12% Intraday chart for Fusen Pharmaceutical Company Limited +1.15% -35.77%
04-04 Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator MT
04-03 Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I) CI

Financials

Sales 2021 386M 53.27M 416M 72.79M Sales 2022 492M 67.93M 531M 92.81M Capitalization 958M 132M 1.03B 181M
Net income 2021 16M 2.21M 17.26M 3.02M Net income 2022 -34M -4.7M -36.69M -6.42M EV / Sales 2021 2.41 x
Net Debt 2021 159M 21.96M 172M 30.01M Net Debt 2022 100M 13.85M 108M 18.93M EV / Sales 2022 2.15 x
P/E ratio 2021
50.5 x
P/E ratio 2022
-25.3 x
Employees 1,148
Yield 2021
0.9%
Yield 2022
-
Free-Float 22.24%
More Fundamentals * Assessed data

Chart Fusen Pharmaceutical Company Limited

Dynamic Chart

Latest news about Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator MT
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I) CI
Fusen Pharmaceutical Posts Higher Loss in 2023 MT
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023 CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Fusen Pharmaceutical Forecasts Return to Profitability in H1 MT
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023 CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023. CI
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired. CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022. CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022 CI
Fusen Pharmaceutical to Swing to Loss in 2022 MT
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022 CI
More news

Press releases Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, RE-APPOINTMENT OF AUDITORS, DECLARATION OF FINAL DIVIDEND, AMENDMENTS TO THE MEMORANDUM AND THE ARTICLES, ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING PU
Fusen Pharmaceutical : Interim Report 2020 PU
Fusen Pharmaceutical : Next Day Disclosure Return PU
Fusen Pharmaceutical : APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR PU
More press releases

Quotes and Performance

1 day-1.12%
1 week+1.15%
Current month-3.30%
1 month-2.22%
3 months-35.77%
6 months-41.33%
Current year-35.77%
More quotes

Highs and lows

1 week
0.76
Extreme 0.76
0.95
1 month
0.76
Extreme 0.76
1.00
Current year
0.76
Extreme 0.76
1.39
1 year
0.76
Extreme 0.76
1.60
3 years
0.76
Extreme 0.76
4.70
5 years
0.76
Extreme 0.76
20.00
10 years
0.76
Extreme 0.76
20.00
More quotes

Managers and Directors - Fusen Pharmaceutical Company Limited

Managers TitleAgeSince
Zhen Li DFI
 Director of Finance/CFO 46 19-04-17
Zhi Ming Cao BRD
 Director/Board Member 38 13-01-17
Tik Man Wong SEC
 Corporate Secretary 43 21-01-28
Members of the board TitleAgeSince
Kwok Tung Lee BRD
 Director/Board Member 56 19-04-14
Chang Cheng Cao CHM
 Chairman 67 16-11-19
Tai Sheng Hou BRD
 Director/Board Member 61 17-04-06
More insiders

Quotes

Date Price Change Volume
24-05-02 0.88 -1.12% 354 000
24-05-02 0.89 0.00% 542,000
24-04-30 0.89 0.00% 0
24-04-29 0.89 -1.11% 498,000
24-04-26 0.9 +3.45% 122,000

Delayed Quote Hong Kong S.E., May 02, 2024 at 09:56 pm

More quotes

Company Profile

Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-27 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
FUSEN PHARMACEUTICAL COMPANY LIMITED Stock Fusen Pharmaceutical Company Limited
-35.77% 84.1M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.61% 43.18B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.59B
SANDOZ GROUP AG Stock Sandoz Group AG
+14.56% 14.56B
CIPLA LIMITED Stock Cipla Limited
+13.94% 13.54B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+43.35% 11.5B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 6.93B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+10.21% 5.36B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1652 Stock